Research
Filter News
Found 146,432 articles
-
South Rampart Pharma Successfully Completes Phase 1 Study and Expands Phase 2 Plans to Include Neuropathic and Acute Pain Trials
1/2/2024
South Rampart Pharma, Inc. announced today that it has successfully completed a Phase 1 trial (NCT05484414).
-
NanoPhoria Bioscience Publishes Groundbreaking Study in Major Cardiology Journal
1/2/2024
NanoPhoria srl, a pre-clinical stage biotech company, is pleased to announce the publication of a groundbreaking study in the field of cardiology, conducted using a clinically relevant pig model of heart failure.
-
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
1/2/2024
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1 -Positive Non-Small Cell Lung Cancer and NTRK -Positive Solid Tumors.
-
SimBioSys and Mayo Clinic Enter Strategic Collaboration to Advance AI-powered Digital Precision Medicine Platform for Cancer Patients
1/2/2024
SimBioSys announced today it has entered into a strategic collaboration agreement with Mayo Clinic for the development of novel digital precision medicine solutions for breast cancer patients.
-
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
1/2/2024
Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today positive interim results from the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 tablet for treatment of patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).
-
Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
1/1/2024
Longboard Pharmaceuticals, Inc. announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a clinical trial evaluating bexicaserin in participants with a broad range of Developmental and Epileptic Encephalopathies.
-
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
12/29/2023
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that the novel adjuvanted recombinant shingles vaccine REC610 independently developed by the Company has recently achieved positive results in the interim analysis of first-in-human clinical trial in the Philippines.
-
Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide
12/29/2023
Newron Pharmaceuticals S.p.A. announced the completion of patient enrollment in study 008A, its potentially pivotal study with evenamide in patients suffering from schizophrenia.
-
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
12/28/2023
Microbot Medical Inc. announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.
-
Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research
12/28/2023
Bionano Genomics, Inc., announced significant upgrades to its pipeline for analysis of optical genome mapping data in its VIA™ software for applications in constitutional genetic disease.
-
Reactivate, repurpose, and rewire the brain
12/28/2023
Developing brains become shaped by the sights, sounds, and experiences of early life. The brain's circuits grow more stable as we age.
-
ChemDiv Forges Strategic Partnership with The University of Texas Medical Branch (UTMB) to Expand Its High-throughput Screening Research Capabilities
12/28/2023
ChemDiv announces a strategic collaboration with the University of Texas Medical Branch to facilitate the expansion of its inventory and advance the institution's High-throughput Screening research programs.
-
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager
12/28/2023
Elpiscience Biopharma, Ltd. and Astellas Pharma Inc. announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019 and another program.
-
Caliway to Present CBL-514 Phase 2 Study Results for Subcutaneous Fat Reduction at IMCAS 2024
12/27/2023
Caliway Biopharmaceuticals announced that the company will present at the 25th IMCAS World Congress on 1-3 February 2024 in Paris, France.
-
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami
12/27/2023
Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001.
-
These worms have rhythm
12/27/2023
There's a rhythm to developing life. Growing from a tiny cell cluster into an adult organism takes precise timing and control.
-
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
12/27/2023
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. and a clinical stage biotechnology company developing ultra-high concentration nitric oxide as an immunotherapeutic for solid tumors, announced that the Phase 1 Study evaluating UNO in advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors has cleared the first cohort of 25,000 ppm single dose UNO by the Safety Review Committee with no reported dose limiting toxicities.
-
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
12/27/2023
SELLAS Life Sciences Group, Inc. announced follow-up clinical/immune-response data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S, combined with the checkpoint inhibitor nivolumab in patients with refractory/relapsed malignant pleural mesothelioma.
-
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)
12/27/2023
Bluejay Diagnostics, Inc., announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients.
-
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
12/27/2023
Kuros Biosciences, a leader in next generation bone graft technologies, announced results from two prospective, randomized clinical studies - the STRUCTURE and MAXA trials.